Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Mylan Expands its Voluntary Nationwide Recall of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, to All Lots Within Expiry Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient


      News provided by

      Mylan N.V.

      Dec 04, 2018, 11:30 ET

      Share this article

      Share this article


      HERTFORDSHIRE, England and PITTSBURGH, Dec. 4, 2018 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced that its U.S. based Mylan Pharmaceuticals business is expanding its consumer-level voluntary nationwide recall to include all lots of Valsartan-containing products within expiry. The 104 additional lots include 26 lots of Amlodipine and Valsartan Tablets, USP (including the 5mg/160mg, 10mg/160mg, 5mg/320mg and 10mg/320mg strengths), 51 lots of Valsartan Tablets, USP (including 40 mg, 80 mg, 160 mg and 320 mg strengths), and 27 lots of Valsartan and Hydrochlorothiazide Tablets, USP (80mg/12.5mg, 160mg/12.5mg, 160mg/25mg, 320mg/12.5mg and 320mg/25mg strengths).  

      Continue Reading
      Mylan N.V.
      Mylan N.V.
      Mylan N.V.
      Mylan N.V.
      Mylan N.V.
      Mylan N.V.
      Mylan N.V.
      Mylan N.V.
      Mylan N.V.
      Mylan N.V.
      Mylan N.V.
      Mylan N.V.
      Mylan N.V.
      Mylan N.V.
      Mylan N.V.
      Mylan N.V.
      Mylan N.V.
      Mylan N.V.
      Mylan N.V.
      Mylan N.V.
      Mylan N.V.
      Mylan N.V.
      Mylan N.V.
      Mylan N.V.
      Mylan N.V.
      Mylan N.V.
      Mylan N.V.
      Mylan N.V.
      Mylan N.V.
      Mylan N.V.
      Mylan N.V.
      Mylan N.V.
      Mylan N.V.
      Mylan N.V.
      Mylan N.V.
      Mylan N.V.
      Mylan N.V.
      Mylan N.V.
      Mylan N.V.
      Mylan N.V.
      Mylan N.V.
      Mylan N.V.
      Mylan N.V.
      Mylan N.V.

      Out of an abundance of caution, these products are being recalled due to detected trace amounts of an impurity, N-nitrosodiethylamine (NDEA) contained in the API Valsartan, USP, manufactured by Mylan Laboratories Limited. NDEA is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen according to the International Agency for Research on Cancer (IARC).

      The finished products are manufactured by Mylan Pharmaceuticals Inc. and Mylan Laboratories Limited. These batches were distributed in the U.S. between March 2017 and November 2018.  The expanded recalled batches are as follows:

      NDC

      Name and Strength

      Size

      Lot No

      Expiry

      0378-1721-93

      Amlodipine and Valsartan Tablets, USP  5/160 mg

      Bottles of 30

      3064084

      1/2019

      0378-1721-93

      Amlodipine and Valsartan Tablets, USP  5/160 mg

      Bottles of 30

      3069629

      5/2019

      0378-1721-93

      Amlodipine and Valsartan Tablets, USP  5/160 mg

      Bottles of 30

      3073148

      8/2019

      0378-1721-93

      Amlodipine and Valsartan Tablets, USP  5/160 mg

      Bottles of 30

      3073149

      8/2019

      0378-1721-93

      Amlodipine and Valsartan Tablets, USP  5/160 mg

      Bottles of 30

      3076093

      10/2019

      0378-1721-93

      Amlodipine and Valsartan Tablets, USP  5/160 mg

      Bottles of 30

      3077772

      11/2019

      0378-1722-93

      Amlodipine and Valsartan Tablets, USP 10/160 mg

      Bottles of 30

      3064085

      1/2019

      0378-1722-93

      Amlodipine and Valsartan Tablets, USP 10/160 mg

      Bottles of 30

      3066063

      3/2019

      0378-1722-93

      Amlodipine and Valsartan Tablets, USP 10/160 mg

      Bottles of 30

      3069638

      5/2019

      0378-1722-93

      Amlodipine and Valsartan Tablets, USP 10/160 mg

      Bottles of 30

      3069639

      6/2019

      0378-1723-93

      Amlodipine and Valsartan Tablets, USP 5/320 mg

      Bottles of 30

      3064086

      1/2019

      0378-1723-93

      Amlodipine and Valsartan Tablets, USP 5/320 mg

      Bottles of 30

      3066061

      3/2019

      0378-1723-93

      Amlodipine and Valsartan Tablets, USP 5/320 mg

      Bottles of 30

      3066062

      3/2019

      0378-1723-93

      Amlodipine and Valsartan Tablets, USP 5/320 mg

      Bottles of 30

      3073145

      9/2019

      0378-1723-93

      Amlodipine and Valsartan Tablets, USP 5/320 mg

      Bottles of 30

      3073146

      9/2019

      0378-1723-93

      Amlodipine and Valsartan Tablets, USP 5/320 mg

      Bottles of 30

      3073147

      9/2019

      0378-1723-93

      Amlodipine and Valsartan Tablets, USP 5/320 mg

      Bottles of 30

      3076091

      11/2019

      0378-1723-93

      Amlodipine and Valsartan Tablets, USP 5/320 mg

      Bottles of 30

      3077619

      11/2019

      0378-1723-93

      Amlodipine and Valsartan Tablets, USP 5/320 mg

      Bottles of 30

      3082432

      3/2020

      0378-1724-93

      Amlodipine and Valsartan Tablets, USP 10/320 mg

      Bottles of 30

      3066064

      3/2019

      0378-1724-93

      Amlodipine and Valsartan Tablets, USP 10/320 mg

      Bottles of 30

      3069645

      6/2019

      0378-1724-93

      Amlodipine and Valsartan Tablets, USP 10/320 mg

      Bottles of 30

      3069646

      6/2019

      0378-1724-93

      Amlodipine and Valsartan Tablets, USP 10/320 mg

      Bottles of 30

      3073142

      9/2019

      0378-1724-93

      Amlodipine and Valsartan Tablets, USP 10/320 mg

      Bottles of 30

      3073143

      9/2019

      0378-1724-93

      Amlodipine and Valsartan Tablets, USP 10/320 mg

      Bottles of 30

      3073144

      9/2019

      0378-1724-93

      Amlodipine and Valsartan Tablets, USP 10/320 mg

      Bottles of 30

      3077617

      11/2019






      NDC

      Name and Strength

      Size

      Lot No

      Expiry

      0378-5807-93

      Valsartan Tablets, USP 40 mg

      Bottles of 30

      3063780

      1/2019

      0378-5807-93

      Valsartan Tablets, USP 40 mg

      Bottles of 30

      3074879

      10/2019

      0378-5807-93

      Valsartan Tablets, USP 40 mg

      Bottles of 30

      3086684

      6/2020

      0378-5807-93

      Valsartan Tablets, USP 40 mg

      Bottles of 30

      3086687

      6/2020

      0378-5813-77

      Valsartan Tablets, USP 80 mg

      Bottles of 90

      3065445

      2/2019

      0378-5813-77

      Valsartan Tablets, USP 80 mg

      Bottles of 90

      3074880

      10/2019

      0378-5813-77

      Valsartan Tablets, USP 80 mg

      Bottles of 90

      3074883

      10/2019

      0378-5813-77

      Valsartan Tablets, USP 80 mg

      Bottles of 90

      3086688

      6/2020

      0378-5813-77

      Valsartan Tablets, USP 80 mg

      Bottles of 90

      3086689

      6/2020

      0378-5813-77

      Valsartan Tablets, USP 80 mg

      Bottles of 90

      3086710

      6/2020

      0378-5814-77

      Valsartan Tablets, USP 160 mg

      Bottles of 90

      3069019

      5/2019

      0378-5814-77

      Valsartan Tablets, USP 160 mg

      Bottles of 90

      3069020

      5/2019

      0378-5814-77

      Valsartan Tablets, USP 160 mg

      Bottles of 90

      3069021

      5/2019

      0378-5814-77

      Valsartan Tablets, USP 160 mg

      Bottles of 90

      3069022

      5/2019

      0378-5814-77

      Valsartan Tablets, USP 160 mg

      Bottles of 90

      3071354

      7/2019

      0378-5814-77

      Valsartan Tablets, USP 160 mg

      Bottles of 90

      3071355

      7/2019

      0378-5814-77

      Valsartan Tablets, USP 160 mg

      Bottles of 90

      3071357

      7/2019

      0378-5814-77

      Valsartan Tablets, USP 160 mg

      Bottles of 90

      3079023

      1/2020

      0378-5814-77

      Valsartan Tablets, USP 160 mg

      Bottles of 90

      3079027

      1/2020

      0378-5814-77

      Valsartan Tablets, USP 160 mg

      Bottles of 90

      3079028

      1/2020

      0378-5814-77

      Valsartan Tablets, USP 160 mg

      Bottles of 90

      3079029

      1/2020

      0378-5814-77

      Valsartan Tablets, USP 160 mg

      Bottles of 90

      3079996

      2/2020

      0378-5814-77

      Valsartan Tablets, USP 160 mg

      Bottles of 90

      3079997

      2/2020

      0378-5814-77

      Valsartan Tablets, USP 160 mg

      Bottles of 90

      3079998

      2/2020

      0378-5814-77

      Valsartan Tablets, USP 160 mg

      Bottles of 90

      3083635

      4/2020

      0378-5814-77

      Valsartan Tablets, USP 160 mg

      Bottles of 90

      3086715

      6/2020

      0378-5814-77

      Valsartan Tablets, USP 160 mg

      Bottles of 90

      3086716

      7/2020

      0378-5814-77

      Valsartan Tablets, USP 160 mg

      Bottles of 90

      3086717

      7/2020

      0378-5814-77

      Valsartan Tablets, USP 160 mg

      Bottles of 90

      3088623

      8/2020

      0378-5815-77

      Valsartan Tablets, USP 320 mg

      Bottles of 90

      3063783

      1/2019

      0378-5815-77

      Valsartan Tablets, USP 320 mg

      Bottles of 90

      3063784

      1/2019

      0378-5815-77

      Valsartan Tablets, USP 320 mg

      Bottles of 90

      3063785

      1/2019

      0378-5815-77

      Valsartan Tablets, USP 320 mg

      Bottles of 90

      3064092

      1/2019

      0378-5815-77

      Valsartan Tablets, USP 320 mg

      Bottles of 90

      3064093

      1/2019

      0378-5815-77

      Valsartan Tablets, USP 320 mg

      Bottles of 90

      3064094

      1/2019

      0378-5815-77

      Valsartan Tablets, USP 320 mg

      Bottles of 90

      3070349

      6/2019

      0378-5815-77

      Valsartan Tablets, USP 320 mg

      Bottles of 90

      3070350

      6/2019

      0378-5815-77

      Valsartan Tablets, USP 320 mg

      Bottles of 90

      3070351

      6/2019

      0378-5815-77

      Valsartan Tablets, USP 320 mg

      Bottles of 90

      3070352

      6/2019

      0378-5815-77

      Valsartan Tablets, USP 320 mg

      Bottles of 90

      3070353

      6/2019

      0378-5815-77

      Valsartan Tablets, USP 320 mg

      Bottles of 90

      3070354

      6/2019

      0378-5815-77

      Valsartan Tablets, USP 320 mg

      Bottles of 90

      3079030

      1/2020

      0378-5815-77

      Valsartan Tablets, USP 320 mg

      Bottles of 90

      3079031

      1/2020

      0378-5815-77

      Valsartan Tablets, USP 320 mg

      Bottles of 90

      3079032

      1/2020

      0378-5815-77

      Valsartan Tablets, USP 320 mg

      Bottles of 90

      3079033

      1/2020

      0378-5815-77

      Valsartan Tablets, USP 320 mg

      Bottles of 90

      3080011

      2/2020

      0378-5815-77

      Valsartan Tablets, USP 320 mg

      Bottles of 90

      3080224

      2/2020

      0378-5815-77

      Valsartan Tablets, USP 320 mg

      Bottles of 90

      3081498

      3/2020

      0378-5815-77

      Valsartan Tablets, USP 320 mg

      Bottles of 90

      3081500

      3/2020

      0378-5815-77

      Valsartan Tablets, USP 320 mg

      Bottles of 90

      3087126

      7/2020

      0378-5815-77

      Valsartan Tablets, USP 320 mg

      Bottles of 90

      3088476

      8/2020






      NDC

      Name and Strength

      Size

      Lot No

      Expiry

      0378-6321-77

      Valsartan and Hydrochlorothiazide Tablets, USP 80/12.5 mg

      Bottles of 90

      3084363

      2/2019

      0378-6321-77

      Valsartan and Hydrochlorothiazide Tablets, USP 80/12.5 mg

      Bottles of 90

      3084364

      2/2019

      0378-6321-77

      Valsartan and Hydrochlorothiazide Tablets, USP 80/12.5 mg

      Bottles of 90

      3093800

      12/2019

      0378-6321-05

      Valsartan and Hydrochlorothiazide Tablets, USP 80/12.5 mg

      Bottles of 500

      3084363

      2/2019

      0378-6321-05

      Valsartan and Hydrochlorothiazide Tablets, USP 80/12.5 mg

      Bottles of 500

      3093800

      12/2019

      0378-6322-77

      Valsartan and Hydrochlorothiazide Tablets, USP 160/12.5 mg

      Bottles of 90

      2008880

      8/2020

      0378-6322-77

      Valsartan and Hydrochlorothiazide Tablets, USP 160/12.5 mg

      Bottles of 90

      3084358

      2/2019

      0378-6322-77

      Valsartan and Hydrochlorothiazide Tablets, USP 160/12.5 mg

      Bottles of 90

      3084359

      2/2019

      0378-6322-77

      Valsartan and Hydrochlorothiazide Tablets, USP 160/12.5 mg

      Bottles of 90

      3093801

      12/2019

      0378-6322-05

      Valsartan and Hydrochlorothiazide Tablets, USP 160/12.5 mg

      Bottles of 500

      3084359

      2/2019

      0378-6322-05

      Valsartan and Hydrochlorothiazide Tablets, USP 160/12.5 mg

      Bottles of 500

      3084361

      2/2019

      0378-6322-05

      Valsartan and Hydrochlorothiazide Tablets, USP 160/12.5 mg

      Bottles of 500

      3093801

      12/2019

      0378-6323-77

      Valsartan and Hydrochlorothiazide Tablets, USP 160/25 mg

      Bottles of 90

      3084887

      2/2019

      0378-6323-77

      Valsartan and Hydrochlorothiazide Tablets, USP 160/25 mg

      Bottles of 90

      3093802

      12/2019

      0378-6323-05

      Valsartan and Hydrochlorothiazide Tablets, USP 160/25 mg

      Bottles of 500

      3084887

      2/2019

      0378-6323-05

      Valsartan and Hydrochlorothiazide Tablets, USP 160/25 mg

      Bottles of 500

      3084888

      2/2019

      0378-6323-05

      Valsartan and Hydrochlorothiazide Tablets, USP 160/25 mg

      Bottles of 500

      3093802

      12/2019

      0378-6324-77

      Valsartan and Hydrochlorothiazide Tablets, USP 320/12.5 mg

      Bottles of 90

      3084889

      2/2019

      0378-6324-77

      Valsartan and Hydrochlorothiazide Tablets, USP 320/12.5 mg

      Bottles of 90

      3093803

      12/2019

      0378-6324-05

      Valsartan and Hydrochlorothiazide Tablets, USP 320/12.5 mg

      Bottles of 500

      3084890

      2/2019

      0378-6324-05

      Valsartan and Hydrochlorothiazide Tablets, USP 320/12.5 mg

      Bottles of 500

      3093803

      12/2019

      0378-6325-77

      Valsartan and Hydrochlorothiazide Tablets, USP 320/25 mg

      Bottles of 90

      3084860

      2/2019

      0378-6325-77

      Valsartan and Hydrochlorothiazide Tablets, USP 320/25 mg

      Bottles of 90

      3084861

      2/2019

      0378-6325-77

      Valsartan and Hydrochlorothiazide Tablets, USP 320/25 mg

      Bottles of 90

      3084862

      2/2019

      0378-6325-77

      Valsartan and Hydrochlorothiazide Tablets, USP 320/25 mg

      Bottles of 90

      3093804

      12/2019

      0378-6325-05

      Valsartan and Hydrochlorothiazide Tablets, USP 320/25 mg

      Bottles of 500

      3084862

      2/2019

      0378-6325-05

      Valsartan and Hydrochlorothiazide Tablets, USP 320/25 mg

      Bottles of 500

      3084863

      2/2019

      Valsartan is used for the treatment of high blood pressure for the treatment of heart failure, and to reduce cardiovascular mortality following myocardial infarction. Valsartan in combination with amlodipine or hydrochlorothiazide is used for the treatment of high blood pressure. Patients should contact their pharmacist or physician who can advise them about an alternative treatment prior to returning their medication. Patients who are on valsartan should continue taking their medication, as the risk of harm to the patient's health may be higher if the treatment is stopped immediately without any alternative treatment.

      Mylan is notifying its distributors and customers by letter and is arranging for return of all recalled products. Wholesalers, retailers and consumers that are in possession of recalled product should contact Stericycle at 1-888-406-9305 for the return of the recalled product. Normal business hours are Monday through Friday 8 a.m. to 5 p.m. EST.

      Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to using these drug products.

      • Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax. Complete and submit the report Online: www.fda.gov/medwatch/report.htm
      • Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form or submit by fax to 1-800-FDA-0178.

      This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

      About Mylan
      Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 7,500 marketed products around the world, including antiretroviral therapies on which more than 40% of people being treated for HIV/AIDS globally depend. We market our products in more than 165 countries and territories. We are one of the world's largest producers of active pharmaceutical ingredients. Every member of our approximately 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time. Learn more at Mylan.com. We routinely post information that may be important to investors on our website at investor.mylan.com.

      Product Photos

      SOURCE Mylan N.V.

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.